Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
China Resources Pharmaceutical Group's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 2.28%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
STU:640's 3-Year ROIIC % is ranked worse than 53.38% of 948
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs STU:640: 2.28
China Resources Pharmaceutical Group (STU:640) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
China Resources Pharmaceutical Group 3-Year ROIIC % Related Terms
China Resources Pharmaceutical Group 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group 3-Year ROIIC % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Pharmaceutical Group 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where China Resources Pharmaceutical Group's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
China Resources Pharmaceutical Group (STU:640) has a 3-Year ROIIC % of 2.28 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on China Resources Pharmaceutical Group and its competitors. This is 54% below median its historical median of 4.99. According to the industry distribution chart, China Resources Pharmaceutical Group ranks #506 out of 948 companies in the Drug Manufacturers industry, placing it in the top 53.4%.
Is China Resources Pharmaceutical Group's 3-Year ROIIC % too high?
China Resources Pharmaceutical Group's current 3-Year ROIIC % of 2.28 is 54% below median its 10-year median of 4.99. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. China Resources Pharmaceutical Group's value of 2.28 is 38.7% below this industry median. Based on the distribution chart, China Resources Pharmaceutical Group ranks #506 out of 948 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, China Resources Pharmaceutical Group has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Pharmaceutical Group ranks #506 out of 948 companies for 3-Year ROIIC %. This places China Resources Pharmaceutical Group in the lower half of its industry. The industry median 3-Year ROIIC % is 3.72. China Resources Pharmaceutical Group's value of 2.28 is 38.7% below this benchmark. While the company's 10-year median is 4.99 vs. the industry median of 3.72, China Resources Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Pharmaceutical Group's current 3-Year ROIIC % of 2.28 is 38.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on China Resources Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Pharmaceutical Group's current 3-Year ROIIC % is 2.28, which is 54% below median its own 10-year median of 4.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.65, compared to a current price of €0.51 — trading 21.5% below its estimated fair value. The current 3-Year ROIIC % is 2.28, which is 54% below median its 10-year median of 4.99 and 38.7% below the Drug Manufacturers industry median of 3.72. China Resources Pharmaceutical Group's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current 3-Year ROIIC % is 2.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.51 is trading 21.5% below its estimated GF Value™ of €0.65.
GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for STU:640:
3-Year ROIIC %: 2.28 (54% below median its 10-year median of 4.99)
GF Value™: €0.65 vs. price of €0.51 (21.5% below fair value)
Industry Position: 38.7% below the Drug Manufacturers median (#506 of 948)
No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Pharmaceutical Group Business Description
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
60GF Score
Get the complete analysis for STU:640
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:640 has been successfully added to your 
